Develop and internally evaluate an architecture-diverse deep-learning ensemble for image-level classification of chest CT images as adenocarcinoma, large cell carcinoma, squamous cell carcinoma, or normal lung, assessing discrimination, calibration, class-specific errors, uncertainty, and uncertainty-based referral.
Approach:
Study design: Retrospective methodological investigation intended to support classification and prioritization for expert review, not replace pathology or radiologist interpretation.
Dataset: Used a publicly available Kaggle dataset containing 1,000 readable JPG, JPEG, or PNG images across the four specified categories. Repository directory labels served as the reference standard.
Evaluation: The planned analyses included validation-based model selection, weighted ensembling, temperature and class-specific decision scaling, calibration assessment, class-specific error analysis, predictive entropy, and uncertainty-based referral.
Key Findings:
The introduction reports strong calibrated discrimination and substantial gains from referral in the analysis.
Adenocarcinoma and squamous cell carcinoma remained a source of confusion.
The supplied context does not provide numerical performance results or details of the data partition.
Interpretation:
The study evaluates an uncertainty-aware ensemble as an assistive approach for image-level classification and prioritization for expert review; it does not propose replacing established diagnostic assessment.
Limitations:
The dataset is retrospective and publicly sourced; the original diagnostic verification methods and annotator qualifications were not reported.
Patient demographics, scanner characteristics, acquisition parameters, and de-identification procedures were unavailable.
Patient and examination counts, and patient-level independence between partitions, could not be determined.
The dataset includes only three NSCLC categories and normal images; small cell lung cancer and other uncommon pulmonary malignancies are absent.
The reference standard consisted solely of repository directory labels, and images were not relabeled.
Harold Burstein, MD, PhD, and Jennifer A. Ligibel, MD discuss new research from the Breast Cancer Weight Loss (BWEL) trial, as well as recommendations for lifestyle, diet and GLP1 agonists.
